ViatrisHAM:VIA +1.71%58 FCF Margin % is 7.51% as of Mar. 2026, which is 40% below its 10-year median of 12.55. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, Viatris ranks better than 73.49% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Viatris's Free Cash Flow for the
three
months ended in Mar. 2026 was €228 Mil. Viatris's Revenue for the
three
months ended in Mar. 2026 was €3,042 Mil. Therefore, Viatris's FCF Margin % for the quarter that ended in Mar. 2026 was 7.51%.
The historical rank and industry rank for Viatris's FCF Margin % or its related term are showing as below:
HAM:VIA'
s FCF Margin % Range Over the Past 10 Years
Min: 4.61 Med: 12.55 Max: 15.43
Current: 11.33
During the past 13 years, the highest FCF Margin % of Viatris was 15.43%. The lowest was 4.61%. And the median was 12.55%.
HAM:VIA's FCF Margin % is ranked better than 73.49% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs HAM:VIA: 11.33
Viatris FCF Margin % Related Terms
Viatris FCF Margin % Historical Data
* Premium members only.
The historical data trend for Viatris's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs NBIX, UTHR, ELAN: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Viatris's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a FCF Margin % of 7.51% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viatris and its competitors. This is 40% below median its historical median of 12.55. Over the past decade, Viatris' FCF Margin % has ranged from 4.61 to 15.43. According to the industry distribution chart, Viatris ranks #254 out of 958 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Viatris' FCF Margin % too high?
Viatris' current FCF Margin % of 7.51% is 40% below median its 10-year median of 12.55. Over the past 10 years, this metric has ranged from a low of 4.61 to a high of 15.43. The Drug Manufacturers industry median FCF Margin % is 2.45. Viatris' value of 7.51% is 207.2% above this industry median. Based on the distribution chart, Viatris ranks #254 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' FCF Margin % compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #254 out of 958 companies for FCF Margin %. This puts Viatris in the upper half of its industry. The industry median FCF Margin % is 2.45. Viatris' value of 7.51% is 207.2% above this benchmark. Historically, Viatris' own FCF Margin % has ranged from 4.61 to 15.43 over the past decade. While the company's 10-year median is 12.55 vs. the industry median of 2.45, Viatris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current FCF Margin % of 7.51% is 207.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current FCF Margin % is 7.51%, which is 40% below median its own 10-year median of 12.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 45.9% above its estimated fair value. The current FCF Margin % is 7.51%, which is 40% below median its 10-year median of 12.55 and 207.2% above the Drug Manufacturers industry median of 2.45. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Viatris (HAM:VIA), the current FCF Margin % is 7.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 45.9% above its estimated GF Value™ of €9.77.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
FCF Margin %: 7.51% (40% below median its 10-year median of 12.55)
GF Value™: €9.77 vs. price of €14.26 (45.9% above fair value)
Industry Position: 207.2% above the Drug Manufacturers median (#254 of 958)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
